plozasiran investigational
Selected indexed studies
- Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia. (J Am Coll Cardiol, 2025) [PMID:40099777]
- Molecular Therapeutics in Development to Treat Hyperlipoproteinemia. (Mol Diagn Ther, 2025) [PMID:39875700]
- A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics. (Mol Ther Nucleic Acids, 2026) [PMID:42112102]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Molecular Therapeutics in Development to Treat Hyperlipoproteinemia. (2025) pubmed
- Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors. (2026) pubmed
- Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia. (2025) pubmed
- A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics. (2026) pubmed